Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM) Meeting Abstract


Authors: Omuro, A. M. P.; Beal, K.; Karimi, S.; Correa, D.; Chan, T. A.; DeAngelis, L. M.; Gavrilovic, I. T.; Nolan, C.; Hormigo, A.; Lassman, A. B.; Kaley, T. J.; Mellinghoff, I. K.; Grommes, C.; Panageas, K.; Reiner, A. S.; Barradas, R.; Abrey, L. E.; Gutin, P. H.
Abstract Title: Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM)
Meeting Title: 47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 29
Issue: 15 Suppl.
Meeting Dates: 2011 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2011-05-20
Language: English
ACCESSION: WOS:000208880301244
PROVIDER: wos
DOI: 10.1200/jco.2011.29.15_suppl.2028
Notes: Meeting Abstract: 2028 -- Source: Wos
Altmetric Score
MSK Authors
  1. Anne S Reiner
    122 Reiner
  2. Timothy Chan
    222 Chan
  3. Denise D Correa
    65 Correa
  4. Philip H Gutin
    153 Gutin
  5. Andrew Lassman
    107 Lassman
  6. Antonio Marcilio Padula Omuro
    177 Omuro
  7. Kathryn Beal
    157 Beal
  8. Sasan Karimi
    97 Karimi
  9. Adilia Hormigo
    48 Hormigo
  10. Thomas Kaley
    90 Kaley
  11. Christian Grommes
    57 Grommes
  12. Lauren E Abrey
    272 Abrey
  13. Katherine S Panageas
    331 Panageas
  14. Craig Nolan
    44 Nolan